| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PLA2R1 |
| Uniprot No | Q13018 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 395-530aa |
| 氨基酸序列 | EEKTWHEALRSCQADNSALIDITSLAEVEFLVTLLGDENASETWIGLSSNKIPVSFEWSNDSSVIFTNWHTLEPHIFPNRSQLCVSAEQSEGHWKVKNCEERLFYICKKAGHVLSDAESGCQEGWERHGGFCYKID |
| 预测分子量 | 19.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PLA2R1重组蛋白的3篇代表性文献，涵盖结构、功能及临床应用方向：
---
1. **文献名称**：*Membranous nephropathy: A model of autoimmune glomerulopathy*
**作者**：Beck LH Jr et al.
**摘要**：该研究首次克隆并鉴定了PLA2R1重组蛋白，证实其为膜性肾病(MN)的主要自身抗原。通过重组蛋白与患者血清抗体的结合实验，揭示了PLA2R1自身抗体在MN诊断中的关键作用，推动了基于重组PLA2R1的血清学检测技术发展。
---
2. **文献名称**：*Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy*
**作者**：Fresquet M et al.
**摘要**：通过重组PLA2R1蛋白的C端结构域(CysR-CTLD1)表达，确定了MN患者自身抗体的主要结合表位。研究揭示了重组蛋白在解析抗原-抗体相互作用机制中的应用，为靶向治疗设计提供了结构基础。
---
3. **文献名称**：*Development of a dual-color time-resolved fluorescence immunoassay for detecting anti-PLA2R1 antibodies*
**作者**：Li X et al.
**摘要**：利用重组PLA2R1蛋白作为抗原，开发了一种高灵敏度的双色时间分辨荧光免疫分析法(TRFIA)，显著提升了MN患者血清中低滴度自身抗体的检出率，验证了重组蛋白在诊断试剂开发中的实用价值。
---
**备注**：如需获取全文或具体发表年份，可进一步通过PubMed/Google Scholar检索标题或作者信息。
**Background of PLA2R1 Recombinant Protein**
The phospholipase A2 receptor 1 (PLA2R1) is a transmembrane glycoprotein belonging to the mannose receptor family, primarily expressed in podocytes of the kidney. It plays a critical role in maintaining glomerular filtration barrier integrity. PLA2R1 gained prominence as a major autoantigen in primary membranous nephropathy (MN), a leading cause of nephrotic syndrome in adults. Approximately 70-80% of primary MN cases are associated with autoantibodies targeting PLA2R1. making it a key biomarker for diagnosis and disease monitoring.
Recombinant PLA2R1 proteins are engineered to mimic the extracellular domain of native PLA2R1. often expressed in mammalian cell systems (e.g., HEK293 cells) to ensure proper glycosylation and conformational fidelity. These proteins retain critical epitopes recognized by autoantibodies, enabling their use in serological assays like ELISA or immunofluorescence to detect anti-PLA2R1 antibodies in patient sera.
Beyond diagnostics, recombinant PLA2R1 facilitates research into disease mechanisms, such as studying antigen-antibody interactions and downstream signaling pathways implicated in podocyte injury. It also serves as a tool for developing targeted therapies, including antigen-specific immunomodulation. Recent studies explore its potential in monitoring treatment efficacy, as antibody titers often correlate with disease activity.
Overall, PLA2R1 recombinant protein is pivotal in advancing understanding and management of autoimmune kidney diseases, bridging translational research with clinical applications.
×
